CN115176005A - 用于治疗血红蛋白病的组合物和方法 - Google Patents
用于治疗血红蛋白病的组合物和方法 Download PDFInfo
- Publication number
- CN115176005A CN115176005A CN202080086828.7A CN202080086828A CN115176005A CN 115176005 A CN115176005 A CN 115176005A CN 202080086828 A CN202080086828 A CN 202080086828A CN 115176005 A CN115176005 A CN 115176005A
- Authority
- CN
- China
- Prior art keywords
- cell
- cells
- population
- molecule
- grna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962950025P | 2019-12-18 | 2019-12-18 | |
| US201962950048P | 2019-12-18 | 2019-12-18 | |
| US62/950,048 | 2019-12-18 | ||
| US62/950,025 | 2019-12-18 | ||
| PCT/IB2020/001098 WO2021123920A1 (en) | 2019-12-18 | 2020-12-16 | Compositions and methods for the treatment of hemoglobinopathies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115176005A true CN115176005A (zh) | 2022-10-11 |
Family
ID=74701511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080086828.7A Pending CN115176005A (zh) | 2019-12-18 | 2020-12-16 | 用于治疗血红蛋白病的组合物和方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230279394A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4077676A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7846007B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN115176005A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021123920A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116445402A (zh) * | 2023-05-09 | 2023-07-18 | 中国科学院生态环境研究中心 | 红系祖细胞的扩增培养基、扩增培养方法及应用 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250179531A1 (en) * | 2022-02-25 | 2025-06-05 | Vor Biopharma Inc. | Compositions and methods for homology-directed repair gene modification |
| US12385408B1 (en) * | 2024-01-26 | 2025-08-12 | Rtx Corporation | Life and performance improvement trenches |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5800815A (en) | 1903-05-05 | 1998-09-01 | Cytel Corporation | Antibodies to P-selectin and their uses |
| US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US6309639B1 (en) | 1991-02-05 | 2001-10-30 | The Board Of Regents Of The University Of Oklahoma | Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand |
| ATE237353T1 (de) | 1992-05-05 | 2003-05-15 | Aeres Biomedical Ltd | Antikörper gegen p-selectin und ihre verwendung |
| US5622701A (en) | 1994-06-14 | 1997-04-22 | Protein Design Labs, Inc. | Cross-reacting monoclonal antibodies specific for E- and P-selectin |
| TW589189B (en) | 1997-08-04 | 2004-06-01 | Scras | Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
| AU776150B2 (en) | 1999-01-28 | 2004-08-26 | Medical College Of Georgia Research Institute, Inc. | Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| EP1235842A4 (en) | 1999-10-15 | 2003-04-23 | Univ Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| JP2004532616A (ja) | 2000-12-28 | 2004-10-28 | ジョンソン・アンド・ジョンソン・リサーチ・ピー・ティー・ワイ・リミテッド | 二本鎖rna仲介遺伝子抑制 |
| AU2004305111B2 (en) | 2003-12-19 | 2011-04-28 | Novartis Vaccines And Diagnostics, Inc. | Cell transfecting formulations of small interfering RNA, related compositions and methods of making and use |
| WO2005100402A1 (en) | 2004-04-13 | 2005-10-27 | F.Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
| PL2662091T3 (pl) | 2006-12-01 | 2019-05-31 | Novartis Ag | Przeciwciała skierowane przeciwko selektynie P i sposoby ich zastosowania do leczenia chorób zapalnych |
| US8945565B2 (en) | 2006-12-01 | 2015-02-03 | Selexys Pharmaceuticals Corporation | Methods of treating inflammatory or thrombotic conditions with anti-P-selectin antibodies |
| US20110212096A1 (en) | 2006-12-01 | 2011-09-01 | Scott Rollins | Anti-p-selectin antibodies and methods of their use and identification |
| WO2009108274A2 (en) * | 2008-02-26 | 2009-09-03 | The University Of North Carolina At Chapel Hill | Methods and compositions for adeno-associated virus (aav) with hi loop mutations |
| PE20100362A1 (es) | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
| WO2011076807A2 (en) | 2009-12-23 | 2011-06-30 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| CN103153284B (zh) | 2010-07-06 | 2015-11-25 | 诺华股份有限公司 | 含有其pKa值有利于RNA递送的脂质的脂质体 |
| EP3542789A3 (en) | 2010-08-31 | 2020-01-01 | GlaxoSmithKline Biologicals SA | Lipids suitable for liposomal delivery of protein-coding rna |
| RU2014104090A (ru) | 2011-07-06 | 2015-08-20 | Новартис Аг | Липосомы с эффективным соотношением n:p для доставки молекул phk |
| WO2013059343A1 (en) | 2011-10-17 | 2013-04-25 | Massachusetts Institute Of Technology | Intracellular delivery |
| US9394547B2 (en) | 2012-01-03 | 2016-07-19 | City University Of Hong Kong | Method and apparatus for delivery of molecules to cells |
| US20130178421A1 (en) | 2012-01-06 | 2013-07-11 | Alcon Research, Ltd. | Interfering rna delivery system and uses thereof |
| SI2807165T1 (sl) | 2012-01-27 | 2019-08-30 | Universite De Montreal | Pirimido(4,5-B)indol derivati in njihova uporaba pri ekspanziji hematopoetskih matičnih celic |
| BR112014020325A2 (pt) * | 2012-02-17 | 2017-08-08 | Childrens Hospital Philadelphia | composições de vetor do aav e métodos para a transferência de gene para as células, órgãos e tecidos |
| US10227610B2 (en) | 2013-02-25 | 2019-03-12 | Sangamo Therapeutics, Inc. | Methods and compositions for enhancing nuclease-mediated gene disruption |
| ES2887254T3 (es) | 2013-03-08 | 2021-12-22 | Novartis Ag | Lípidos y composiciones lipídicas para el suministro de agentes activos |
| EP2968295A1 (en) | 2013-03-15 | 2016-01-20 | Global Blood Therapeutics, Inc. | Compositions and methods for the modulation of hemoglobin (s) |
| PL2970948T3 (pl) | 2013-03-15 | 2019-06-28 | Glaxosmithkline Biologicals Sa | Sposoby oczyszczania rna |
| US10124336B2 (en) | 2013-08-16 | 2018-11-13 | Massachusetts Institute Of Technology | Selective delivery of material to cells |
| US10426737B2 (en) | 2013-12-19 | 2019-10-01 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| US10059655B2 (en) | 2013-12-19 | 2018-08-28 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| EP3129485B2 (en) * | 2014-04-09 | 2022-12-21 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating cystic fibrosis |
| WO2018071871A1 (en) | 2016-10-13 | 2018-04-19 | President And Fellows Of Harvard College | Compositions and methods for non-myeloablative conditioning |
| US20180135080A1 (en) * | 2016-11-15 | 2018-05-17 | Genomic Vision Sa | Method for the monitoring of modified nucleases induced-gene editing events by molecular combing |
| US20180305719A1 (en) * | 2017-04-19 | 2018-10-25 | The Board Of Trustees Of The University Of Illinois | Vectors For Integration Of DNA Into Genomes And Methods For Altering Gene Expression And Interrogating Gene Function |
| EP3731849A4 (en) * | 2017-12-28 | 2021-12-01 | Codiak BioSciences, Inc. | EXOSOME FOR IMMUNONCOLOGICAL AND ANTI-INFLAMMATORY THERAPY |
| US20190345516A1 (en) * | 2018-03-12 | 2019-11-14 | Musc Foundation For Research Development | Methods for treating eye disease |
-
2020
- 2020-12-16 JP JP2022536699A patent/JP7846007B2/ja active Active
- 2020-12-16 EP EP20855886.6A patent/EP4077676A1/en active Pending
- 2020-12-16 CN CN202080086828.7A patent/CN115176005A/zh active Pending
- 2020-12-16 WO PCT/IB2020/001098 patent/WO2021123920A1/en not_active Ceased
- 2020-12-16 US US17/786,347 patent/US20230279394A1/en not_active Abandoned
-
2026
- 2026-04-02 JP JP2026060998A patent/JP2026126214A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116445402A (zh) * | 2023-05-09 | 2023-07-18 | 中国科学院生态环境研究中心 | 红系祖细胞的扩增培养基、扩增培养方法及应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023506842A (ja) | 2023-02-20 |
| EP4077676A1 (en) | 2022-10-26 |
| JP7846007B2 (ja) | 2026-04-14 |
| WO2021123920A1 (en) | 2021-06-24 |
| US20230279394A1 (en) | 2023-09-07 |
| JP2026126214A (ja) | 2026-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12559748B2 (en) | Compositions and methods for the treatment of hemoglobinopathies | |
| JP7844400B2 (ja) | 異常ヘモグロビン症の治療用組成物および方法 | |
| JP2023123561A (ja) | 移植を改善するためのcrispr/cas関連方法および組成物 | |
| JP2025020189A (ja) | 幹細胞における遺伝子編集のための最適化crispr/cas9システムおよび方法 | |
| JP7846007B2 (ja) | 異常ヘモグロビン症の治療用組成物及び方法 | |
| RU2834231C2 (ru) | Композиции и способы, предназначенные для лечения гемоглобинопатий | |
| HK40080440A (en) | Compositions and methods for the treatment of hemoglobinopathies | |
| BR112019016205B1 (pt) | Molécula de grna, composição, uso desta e métodos para alteração e para preparação de uma célula tronco hematopoiética ou célula progenitora hematopoiética (hpc) | |
| BR112018013065B1 (pt) | Molécula de grna, composições, sequência de ácidos nucléicos, vetor, seus respectivos usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |